Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04622891|
Recruitment Status : Completed
First Posted : November 10, 2020
Last Update Posted : November 10, 2020
|Condition or disease||Intervention/treatment||Phase|
|Covid19||Drug: Clarithromycin 500mg Drug: Azithromycin Drug: Placebo||Not Applicable|
The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough.
All study participants underwent full clinical evaluation including duration of fever, cough, dyspnea, anosmia or GIT symptoms, C-reactive protein (CRP), serum ferritin, D-dimer, Complete blood count (CBC), non-contrast chest computed tomography (CT) which was repeated 2 weeks after the start of treatment.
The Azithromycin group included, 107 patients, mean age 45.8 ±18 years, 73 male and 34 female, the Clarithromycin group included 99 patients mean age 46.1±19 years, 68 males and 31 female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28 female.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||clarithomycin group Azithromycin group control group|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial|
|Actual Study Start Date :||April 1, 2020|
|Actual Primary Completion Date :||July 30, 2020|
|Actual Study Completion Date :||July 30, 2020|
Drug: Clarithromycin 500mg
Other Name: active
Active Comparator: Azithromycin
Other Name: active comparison
Placebo Comparator: control
Other Name: control group
- time to fever control [ Time Frame: 15 days ]time to complete resolution of fever
- PCR conversion [ Time Frame: 15 days ]time to PCR conversion from first positive PCR for COVID-19 to negative PCR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04622891
|south-Vally University faculty of medicine|
|Qena, Egypt, 868532|
|Principal Investigator:||Alaa Rashad, MD||associate professor|